ACET Stock Summary and Trading Ideas (Adicet Bio | NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Adicet Bio trades on the NASDAQ stock market under the symbol ACET.

As of November 9, 2026, ACET stock price declined to $2.99 with 170,831 million shares trading.

ACET has a beta of 2.45, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.17 to the broad based SPY ETF.

ACET has a market cap of $27.99 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ACET traded as high as $60.32 and as low as $2.87.

The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAS.

ACET has underperformed the market in the last year with a price return of -70.8% while the SPY ETF gained +13.3%. ACET has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.5% and -24.1%, respectively, while the SPY returned -2.4% and -1.7%, respectively.

ACET support price is $2.86 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.